【摘要】：背景:強(qiáng)直性脊柱炎(Ankylosing Spondylitis,AS)屬慢性炎癥性的自身免疫性的疾病,可造成髖關(guān)節(jié)破壞和脊柱強(qiáng)直,嚴(yán)重影響患者的工作能力和生活自理能力,降低患者的生活質(zhì)量。炎癥是AS首要病理改變。輔助性T細(xì)胞(Thelper cell 17,Th17)是觸發(fā)AS炎癥的重要效應(yīng)細(xì)胞,由初始CD4+T細(xì)胞(Naive CD4+T cell)分化而來。研究表明,表觀遺傳調(diào)控機(jī)制在CD4+T細(xì)胞向Th17分化中扮演著重要角色,組蛋白去甲基化酶JMJD3催化H3K27位點(diǎn)去甲基化,可能是Th17分化的關(guān)鍵調(diào)控因子。在前期臨床研究中,我們發(fā)現(xiàn)清熱利濕活血法緩解AS炎癥的臨床療效滿意。且經(jīng)清熱利濕活血方治療后,AS患者IL-17表達(dá)水平顯著下降,Th17數(shù)量及特征性轉(zhuǎn)錄因子RORc表達(dá)明顯減少,JAK/STAT通路活化水平顯著下降,表明清熱利濕活血法可以通過干預(yù)Th17分化,發(fā)揮緩解AS炎癥的作用。本研究基于此,進(jìn)一步探究JMJD3調(diào)控AS Th17分化的表觀遺傳機(jī)制及清熱利濕活血法的干預(yù)作用。目的:初步探究AS患者JMJD3表達(dá)情況及其去甲基化H3K27對(duì)Th17分化的干預(yù)作用;中藥清熱強(qiáng)脊湯治療及中藥單體雷公藤甲素體外干預(yù)PBMC對(duì)AS患者JMJD3的表達(dá)及Th17分化的調(diào)節(jié)作用。方法:研究一、研究二及研究三以活動(dòng)期AS患者的血清及PBMC為研究對(duì)象,運(yùn)用Western Blotting檢測蛋白表達(dá)情況,Quantitative Real-time PCR等技術(shù)檢測mRNA表達(dá)情況,ELISA檢測血清炎性細(xì)胞因子分泌情況。分別檢測疾病活動(dòng)期、疾病相對(duì)穩(wěn)定期、中藥治療3個(gè)月對(duì)AS患者JMJD3表達(dá)、H3K27me3的甲基化情況及Th17分化狀況的影響作用。研究四以體外分離培養(yǎng)的活動(dòng)期AS患者外周血PBMC為研究對(duì)象,運(yùn)用Western Blotting檢測蛋白表達(dá)情況,Quantitative Real-time PCR等技術(shù)檢測mRNA表達(dá)情況,研究中藥雷公藤有效單體雷公藤甲素體外干預(yù)對(duì)AS患者JMJD3表達(dá)、JMJD3催化的H3K27去甲基化情況及Th17分化狀況的影響作用。結(jié)果:1.活動(dòng)期AS患者JMJD3表達(dá)情況分析中,發(fā)現(xiàn)活動(dòng)期AS患者血清中Th17特異性分泌的細(xì)胞因子IL-17表達(dá)水平較正常對(duì)照組顯著增高,且差異具有統(tǒng)計(jì)學(xué)意義(p0.001);與患者炎癥指標(biāo)ESR、CRP以及疾病活動(dòng)指數(shù)BASDAI做了相關(guān)性分析,發(fā)現(xiàn)IL-17、ESR、CRP互相高度相關(guān)(IL-17-ESR:p0.001;IL-17-CRP:p0.01)�；顒�(dòng)期 AS 患者 PBMC 中,JMJD3 的 mRNA表達(dá)水平較正常對(duì)照顯著增高,(p0.001);JMJD3與炎癥指標(biāo)ESR、CRP間均顯著相關(guān)(ESR:r= 0.631,p=0.0030.01)(CRP:r= 0.567,p=0.0090.01)。JMJD3與炎性細(xì)胞因子IL-17間顯著相關(guān)(IL-17:p0.01),而JMJD3、IL-17與BASDAI均無明顯相關(guān)性關(guān)系。2.活動(dòng)期AS患者JMJD3去甲基化H3K27及對(duì)Th17分化的干預(yù)作用研究中,檢測AS患者(AS-Active)、穩(wěn)定期AS患者(AS-Stable)、正常對(duì)照組(N)的JMJD3、H3K27me3、JAK/STAT信號(hào)通路及特征性轉(zhuǎn)錄因子RORc蛋白及mRNA表達(dá)水平。活動(dòng)期AS患者的JMJD3蛋白表達(dá)水平顯著高于正常對(duì)照組與非活動(dòng)期AS患者(p0.001),而非活動(dòng)期AS患者的JMJD3蛋白表達(dá)水平則與正常對(duì)照無明顯差異(p0.05)。在基因水平上,活動(dòng)期AS患者的JMJD3 mRNA表達(dá)水平較正常對(duì)照組及與非活動(dòng)期AS患者均顯著增高,非活動(dòng)期AS患者較正常對(duì)照組則無明顯差異(AS-Active:p0.001;AS-Stable:p0.05),活動(dòng)期與非活動(dòng)期AS患者間JMJD3的mRNA表達(dá)水平亦存在顯著差異(p0.001)。活動(dòng)期AS患者的H3K27me3甲基化水平均顯著降低,較正常對(duì)照組差異有統(tǒng)計(jì)學(xué)意義(p0.01);活動(dòng)期AS患者與非活動(dòng)期AS患者的H3K27甲基化水平亦存在明顯差異(p0.001),正常對(duì)照組與非活動(dòng)期AS患者無明顯差異(p0.05)。JAK/STAT信號(hào)通路中信號(hào)分子STAT3的磷酸化水平(pSTAT3/STAT3)較正常對(duì)照顯著升高(AS-Active:p0.001;AS-Stable:p0.01)。與非活動(dòng)期患者相比較,活動(dòng)期AS患者JAK2的表達(dá)水平雖沒有明顯差異,但磷酸化的JAK2表達(dá)水平顯著增高(p=0.0130.05);STAT3的蛋白表達(dá)水平及磷酸化水平均較非活動(dòng)期AS患者明顯增高(STAT3:p0.01;pSTAT3:p0.001)。在基因水平上,活動(dòng)期AS患者及非活動(dòng)期AS患者的JAK2及STAT3 mRNA表達(dá)水平均明顯高于正常對(duì)照組(AS-Active:p0.001;AS-Stable:p0.01);而相較于非活動(dòng)期AS患者,活動(dòng)期AS患者上述信號(hào)分子的mRNA表達(dá)量亦存在明顯差異(p0.001)�；顒�(dòng)期AS患者與非活動(dòng)期AS患者轉(zhuǎn)錄因子RORc表達(dá)水平較正常對(duì)照組顯著增高(p0.001);活動(dòng)期AS患者的RORc表達(dá)水平較非活動(dòng)期無明顯差異(p0.05)。在基因表達(dá)水平上,相較于正常對(duì)照組,活動(dòng)期AS患者及非活動(dòng)期AS患者RORc的mRNA均顯著增高(p0.01);活動(dòng)期AS患者與非活動(dòng)期AS患者直接亦存在表達(dá)差異(p0.01)。3.在清熱利濕活血法對(duì)活動(dòng)期AS患者JMJD3表達(dá)及Th17分化的調(diào)節(jié)作用研究中,我們選用本科治療活動(dòng)期骨痹的臨床有效方劑清熱強(qiáng)脊湯辨證治療濕熱瘀阻證的AS患者,并在服藥3個(gè)月后檢測其Th17細(xì)胞的活性與功能。經(jīng)清熱強(qiáng)脊湯治療3個(gè)月后,患者ESR、CRP、BASDAI均較治療前明顯下降,差異有統(tǒng)計(jì)學(xué)意義(p0.001)。治療后患者血清炎性細(xì)胞因子IL-17的表達(dá)水平較治療前也明顯下降(p0.05);JMJD3的蛋白和mRNA表達(dá)情況和相對(duì)灰度值變化均較治療前存在顯著差異(p0.05);患者H3K27me3的甲基化水平均較治療前也表現(xiàn)出了顯著下降(p0.001);患者RORc的基因及蛋白表達(dá)水平均較治療前顯著下降(p0.001)。4.以雷公藤提取物雷公藤甲素干預(yù)活動(dòng)期AS患者的PBMC,經(jīng)雷公藤甲素干預(yù)后,AS患者的JMJD3蛋白表達(dá)水平較干預(yù)前顯著降低(p0.001);基因水平的檢測得到了相同的結(jié)果(p0.001)。經(jīng)雷公藤甲素干預(yù)后,H3K27甲基化水平較治療前顯著提高,差異具有統(tǒng)計(jì)學(xué)意義(p0.001);雷公藤甲素干預(yù)后的H3K27me3水平與正常對(duì)照組則無明顯統(tǒng)計(jì)學(xué)差異(p=0.080.05)。經(jīng)雷公藤甲素干預(yù)后,患者JAK2/STAT3信號(hào)通路的活化被明顯抑制,各信號(hào)分子的磷酸化水平顯著下降(p0.001)�；蛩缴�,JAK2、STAT3的mRNA表達(dá)量明顯下降(p0.001)。經(jīng)雷公藤甲素干預(yù)后,RORc的蛋白和mRNA表達(dá)量顯著下降(p0.001)。結(jié)論:1.JMJD3是Th17分化及功能的重要調(diào)控因子,參與了活動(dòng)期AS的炎癥發(fā)生。JMJD3的表達(dá)水平與Th17的分化及功能高度相關(guān);JMJD3與AS炎癥指標(biāo)也密切相關(guān),可能是控制AS炎癥有意義的治療靶點(diǎn)之一。2.AS患者存在著JMJD3的高度表達(dá)和總體H3K27me3甲基化水平的下降,且在疾病不同活動(dòng)階段的JMJD3表達(dá)水平和H3K27甲基化水平存在明顯差異。同時(shí)不同疾病活動(dòng)階段的患者,其RORc表達(dá)、JAK/STAT信號(hào)通路活化及IL-17分泌均存在差異。JMJD3調(diào)控的H3K27me3去甲基化,可能是干預(yù)Th17的分化、活化及功能,從而影響AS炎癥及疾病活動(dòng)機(jī)制之一。3.清熱利濕活血法對(duì)患者的炎癥指標(biāo)及疾病活動(dòng)都有較好的控制作用,可干預(yù)JMJD3的表達(dá)水平,以及JMJD3催化的H3K27me3去甲基化活性,從而影響表觀遺傳調(diào)控的Th17分化,使RORc的表達(dá)水平和JAK/STAT信號(hào)通路的活化水平降低,從而干預(yù)了Th17的活化及IL-17的表達(dá)。我們推測,清熱利濕活血法對(duì)AS炎癥的緩解作用,可能是通過干預(yù)JMJD的活化與功能,從而抑制Th17的分化、活化以及功能而實(shí)現(xiàn)的。4.中藥單體雷公藤甲素體外干預(yù),可降低AS患者PBMC中JMJD3的表達(dá)水平,影響JMJD3調(diào)控的H3K27me3去甲基化過程,從而使Th17轉(zhuǎn)錄因子RORc、信號(hào)通路JAK/STAT及IL-17的轉(zhuǎn)錄抑制和蛋白表達(dá)被抑制,可能是調(diào)節(jié)Th17的分化偏移及功能,從而緩解AS炎癥的有意義的治療藥物之一。
[Abstract]:BACKGROUND: Ankylosing Spondylitis (AS) is a chronic inflammatory autoimmune disease, which can cause hip joint destruction and spinal rigidity, seriously affect the working ability and self-care ability of patients, and reduce the quality of life of patients. Inflammation is the primary pathological change of AS. The helper T cell (Th17) is the trigger of A. The important effector cells of S inflammation are differentiated from the initial CD4 + T cells. Studies have shown that epigenetic regulation plays an important role in the differentiation of CD4 + T cells into Th17. Histone demethylase JMJD3 catalyzes the demethylation of H3K27 site and may be a key regulator of Th17 differentiation. They found that the method of clearing away heat and dampness and activating blood circulation has a satisfactory clinical effect on alleviating inflammation of AS. After treatment with the prescription of clearing away heat and removing dampness and activating blood circulation, the level of IL-17 expression, the number of Th17 and the expression of RORc, the activation level of JAK/STAT pathway were significantly decreased in AS patients, indicating that the method of clearing away heat and removing dampness and activating blood circulation could be exerted by interfering the differentiation of Th17. Objective: To investigate the expression of JMJD3 and the effect of demethylated H3K27 on the differentiation of Th17 in AS patients. Methods: Study 1, Study 2 and Study 3 were used to detect the expression of JMJD3 and the differentiation of Th17 in the serum and PBMC of AS patients in active phase. The expression of JMJD3 and Th17 mRNA were detected by Western Blotting, Quantitative Real-time PCR and serum inflammatory cytokines were detected by ELISA. Secretion of JMJD3, methylation of H3K27me3 and differentiation of Th17 in AS patients were detected at active stage, relatively stable stage, and three months after treatment with Chinese herbs. Objective:To study the effect of triptolide on the expression of JMJD3, the demethylation of H3K27 catalyzed by JMJD3 and the differentiation of Th17 in AS patients in vitro. Results:1. The expression of Th17 in AS patients in active phase was detected by the analysis of JMJD3 expression. The expression of cytokine IL-17 in heterosexual secretion was significantly higher than that in normal control group (p0.001), and the difference was statistically significant (p0.001); the correlation analysis with inflammatory markers ESR, CRP and disease activity index BASDAI showed that IL-17, ESR and CRP were highly correlated (IL-17-ESR: p0.001; IL-17-CRP: p0.01). The expression of JMJD3 mRNA was significantly higher than that of normal controls (p0.001); JMJD3 was significantly correlated with inflammatory markers ESR and CRP (ESR: r = 0.631, P = 0.0030.01) (CRP: r = 0.567, P = 0.0090.01). JMJD3 was significantly correlated with inflammatory cytokine IL-17 (IL-17: p0.01), but JMJD3, IL-17 were not significantly correlated with BASDAI.2. The expression of JMJD3, H3K27me3, JAK/STAT signaling pathway and characteristic transcription factor RORc protein and mRNA in AS patients (AS-Active), AS-Stable patients (AS-Stable), normal control group (N), and active AS patients were detected. The expression level of JMJD3 mRNA in active AS patients was significantly higher than that in non-active AS patients and normal AS patients (p 0.001), but not in active AS patients (p 0.05). There were significant differences in the expression of JMJD3 mRNA between active and inactive AS patients (p0.001). The methylation level of H3K27me3 in active AS patients was significantly lower than that in normal control group (p0.01). The methylation level of H3K27 in active AS patients and inactive AS patients was also significantly lower than that in normal control group (p0.01). The phosphorylation level of STAT3 in JAK / STAT signaling pathway (pSTAT3 / STAT3) was significantly higher than that in normal controls (AS-Active: p0.001; AS-Stable: p0.01). Compared with non-active patients, the expression level of JAK2 in active AS patients was not significantly different. However, the expression of phosphorylated JAK2 was significantly increased (p=0.0130.05), and the expression of STAT3 protein and phosphorylation were significantly higher than those of inactive AS patients (STAT3:p0.01; pSTAT3:p0.001). At the gene level, the expression of JAK2 and STAT3 mRNA in active AS patients and inactive AS patients were significantly higher than those of normal control group (AS-Active:p0.01). The expression level of RORc in active AS patients and inactive AS patients was significantly higher than that in normal control group (p0.001), while the expression level of RORc in active AS patients was significantly higher than that in inactive AS patients (p0.001). The expression of RORc mRNA was significantly higher in active AS patients and inactive AS patients than in normal control group (p0.01). The expression of JMJD3 and Th17 was also significantly different in active AS patients and inactive AS patients (p0.01). 3. The regulation of heat-clearing, dampness-activating and Blood-Activating Therapy on on JMJD3 expression and Th17 differentiation in active AS patients. In the study of action, we chose Qingre Qiangji Decoction, a clinical effective prescription for active bone arthralgia, to treat AS patients with dampness-heat-stasis syndrome, and detected the activity and function of Th17 cells 3 months after taking the medicine. After treatment, the levels of serum inflammatory cytokine IL-17 were also significantly lower than before treatment (p0.05); JMJD3 protein and mRNA expression and relative gray value changes were significantly different than before treatment (p0.05); H3K27me3 methylation levels in patients were also significantly lower than before treatment (p0.001); The expression of JMJD3 protein in active AS patients treated with triptolide was significantly lower than that before treatment (p0.001). The same result was obtained by gene level detection (p0.001). Dry triptolide was used to treat active AS patients with PBMC. Prognosis, H3K27 methylation level was significantly higher than before treatment, the difference was statistically significant (p0.001); Tripterygium wilfordii intervention H3K27me3 level and normal control group, there was no significant difference (p = 0.080.05). After triptolide intervention, JAK2 / STAT3 signal pathway activation was significantly inhibited, each signal molecule phosphorylated water. At the gene level, JAK2 and STAT3 mRNA expression decreased significantly (p0.001). After triptolide intervention, RORc protein and mRNA expression decreased significantly (p0.001). Conclusion: 1. JMJD3 is an important regulator of Th17 differentiation and function, and participates in the inflammation of active AS. JMJD3 is also closely related to the inflammation index of AS, and may be one of the therapeutic targets for controlling inflammation of AS. 2. There is a high expression of JMJD3 and a decrease of H3K27me3 methylation in AS patients. There are differences in RORc expression, JAK/STAT signaling pathway activation and IL-17 secretion in patients with active disease. H3K27me3 demethylation regulated by JMJD3 may interfere with the differentiation, activation and function of Th17, thus affecting the inflammation and disease activity of AS. 3. Clearing away heat, eliminating dampness and activating blood circulation method has a better effect on inflammatory indexes and disease activity of patients. Controlling effect can interfere with the expression of JMJD3 and the demethylation activity of H3K27me3 catalyzed by JMJD3, thus affecting the Th17 differentiation of epigenetic regulation, reducing the expression of RORc and the activation of JAK/STAT signaling pathway, thus interfering with the activation of Th17 and the expression of IL-17. Mitigation may be achieved by interfering with the activation and function of JMJD, thereby inhibiting the differentiation, activation and function of Th17. 4. Tripterygium Wilfordii in vitro can reduce the expression of JMJD3 in PBMC of AS patients, and affect the H3K27me3 demethylation process regulated by JMJD3, thus making Th17 transcription factor RORc, JAK/STAT signaling pathway. Inhibition of transcriptional and protein expression of IL-17 and IL-17 may be one of the significant therapeutic drugs to alleviate AS inflammation by regulating the differentiation and function of Th17.
【學(xué)位授予單位】：中國中醫(yī)科學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉文成;譚布珍;方玉婷;占欣璐;王玉;;植物雷公藤主要抗癌抗炎活性成分研究進(jìn)展[J];中國臨床藥理學(xué)與治療學(xué);2017年03期

2 董興剛;安增梅;過源;周佳亮;秦濤;;Effect of Triptolide on Expression of Oxidative Carbonyl Protein in Renal Cortex of Rats with Diabetic Nephropathy[J];Journal of Huazhong University of Science and Technology(Medical Sciences);2017年01期

3 文瓊芳;黃烽;;強(qiáng)直性脊柱炎的治療[J];臨床薈萃;2016年05期

4 吳超;婁玉鈐;楊亞飛;許平英;;強(qiáng)直性脊柱炎中醫(yī)辨證分型研究進(jìn)展[J];風(fēng)濕病與關(guān)節(jié)炎;2015年06期

5 鄒玉明;蔡顏榮;徐衛(wèi)東;;強(qiáng)直性脊柱炎發(fā)病過程中炎癥與骨化的關(guān)系[J];中國矯形外科雜志;2015年07期

6 李春杏;李太生;朱珠;謝靜;呂瑋;;雷公藤抗炎免疫調(diào)節(jié)活性單體的研究進(jìn)展[J];中國中藥雜志;2014年21期

7 姜楠;張羽;劉夢(mèng)玉;劉宏瀟;馮興華;;補(bǔ)腎活血法治療強(qiáng)直性脊柱炎研究現(xiàn)狀[J];中國中醫(yī)藥信息雜志;2014年01期

8 馮興華;姜泉;劉宏瀟;王海隆;何夏秀;張華東;唐曉頗;許鳳全;劉健;周翠英;劉維;周彩云;高明利;李振彬;姜楠;曹煒;;中醫(yī)辨證治療強(qiáng)直性脊柱炎的臨床療效評(píng)價(jià)[J];中國中西醫(yī)結(jié)合雜志;2013年10期

9 王智民;鄭洪新;;中醫(yī)“腎主骨”之理論內(nèi)涵及臨床意義[J];中華中醫(yī)藥學(xué)刊;2013年07期

10 姜楠;馮興華;王冬峰;何夏秀;;馮興華教授治療強(qiáng)直性脊柱炎用藥規(guī)律分析[J];吉林中醫(yī)藥;2012年05期

相關(guān)博士學(xué)位論文 前3條

1 梁煒;腎康丸對(duì)糖尿病腎病大鼠的腎保護(hù)作用及對(duì)miR-192信號(hào)通路的影響[D];南方醫(yī)科大學(xué);2009年

2 曾石坤;強(qiáng)直性脊柱炎中醫(yī)臨床辨證論治研究[D];廣州中醫(yī)藥大學(xué);2008年

3 劉宏瀟;補(bǔ)腎活血法治療強(qiáng)直性脊柱炎臨床研究及抗骨化作用實(shí)驗(yàn)探討[D];中國中醫(yī)研究院;2005年

相關(guān)碩士學(xué)位論文 前4條

1 陳鵬;從IL-23/Th17炎癥軸探討清熱活血法抗強(qiáng)直性脊柱炎炎癥的分子機(jī)制[D];北京中醫(yī)藥大學(xué);2014年

2 何夏秀;馮興華教授治療風(fēng)濕病的學(xué)術(shù)經(jīng)驗(yàn)繼承研究[D];中國中醫(yī)科學(xué)院;2012年

3 薛鑫凱;清熱強(qiáng)脊湯治療濕熱痹阻型強(qiáng)直性脊柱炎的臨床研究[D];北京中醫(yī)藥大學(xué);2011年

4 袁永;現(xiàn)代名老中醫(yī)治療強(qiáng)直性脊柱炎的經(jīng)驗(yàn)[D];北京中醫(yī)藥大學(xué);2008年

，

本文編號(hào)：2192400